Atrium Therapeutics Posts 25-Cent Quarterly Loss as Cash Burn Draws Scrutiny
RNA is trading near its 52-week low of $7.49 (0.9% above the low).
Summary
Atrium Therapeutics reported a third-quarter loss of 25 cents a share, or $4.27 million. The company is trading near its 52-week low of $7.49, so the print lands on a stock already under pressure. This follows the $50 million PIPE priced at $7.93 a share in October and Yakira Capital's public push for a strategic review and spending cuts. The loss keeps the focus on burn rate, with cash runway now extending through 2028, and third-quarter collaboration revenue rose on a BMS milestone. The Corventis Phase 1/2 trial of ATR 1072, which dosed its first patient in late October, is the main clinical item on the calendar.
At the time of this announcement, RNA was trading at $7.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $167.1M. The 52-week trading range was $7.49 to $16.77. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.